Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models

Growth Hormone and IGF Research

Volumn 18, Issue 6, 2008, Pages 487-496

  Alami, Nezha ^a   Page, Viviane ^a   Yu, Qingnan ^a   Jerome, Lori ^a   Paterson, Jesse ^a   Shiry, Laura ^b   Leyland Jones, Brian ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Insmed Incorporated   (United States)

Author keywords

Colon cancer; Interaction with chemotherapy; Lung cancer; rhIGFBP 3

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; IRINOTECAN; PROTEIN KINASE B; RECOMBINANT HUMAN INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME PHOSPHORYLATION; LUNG CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 53249138207     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.04.002     Document Type: Article

References (38)

1. Jerome L., Shiry L., and Leyland-Jones B. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocrinol. Relat. Cancer 10 (2003) 561-578
2. Ibrahim Y.H., and Yee D. Insulin-like growth factor-I and breast cancer therapy. Clin. Cancer Res. 11 (2005) 944s-950s
3. Yee D. Targeting insulin-like growth factor pathways. Br. J. Cancer 96 Suppl. (2007) R7-R10
4. Wang Y., and Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target, blocking transformation and inducing apoptosis. Curr. Cancer Drug Targets 2 (2002) 191-207
5. Burger A.M., Leyland-Jones B., Banerjee K., Spyropoulos D.D., and Seth A.K. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur. J. Cancer 41 (2005) 1515-1527
6. Rajah R., Valentinis B., and Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 272 (1997) 12181-12188
7. Liu B., Lee H.Y., Weinzimer S.A., et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J. Biol. Chem. 275 (2000) 33607-33613
8. Schedlich L.J., Le Page S.L., Firth S.M., et al. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J. Biol. Chem. 275 (2000) 23462-23470
9. Perks C.M., McCaig C., Clarke J.B., Clemmons D.R., and Holly J.M. A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. Biochem. Biophys. Res. Commun. 294 (2002) 988-994
10. Yu H., Spitz M.R., Mistry J., et al. Plasma levels of insulin-like growth factor-I and lung cancer risk, a case-control analysis. J. Natl. Cancer Inst. 91 (1999) 151-156
11. Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91 (1999) 620-625
12. Yu H., and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. 92 (2000) 1472-1489
13. Giovannucci E. Insulin, insulin-like growth factors and colon cancer, a review of the evidence. J. Nutr. 131 (2001) 3109S-3120S
14. Renehan A.G., Zwahlen M., Minder C., et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk, systematic review and meta-regression analysis. Lancet 363 (2004) 1346-1353
15. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4 (2004) 505-518
16. Chang Y.S., Kong G., Sun S., et al. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin. Cancer Res. 8 (2002) 3796-3802
17. Izycki T., Chyczewska E., Naumnik W., and Ossolinska M. Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy. Oncol. Res. 16 (2006) 49-54
18. Lee H.Y., Chun K.H., Liu B., et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res. 62 (2002) 3530-3537
19. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin. Cancer Res. 11 (2005) 1563-1571
20. Durai R., Yang W., Gupta S., Seifalian A.M., and Winslet M.C. The role of the insulin-like growth factor system in colorectal cancer, review of current knowledge. Int. J. Colorectal Dis. 20 (2005) 203-220
21. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin. 50 (2000) 7-33
22. Hakam A., Yeatman T.J., Lu L., et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol. 30 (1999) 1128-1133
23. Palmqvist R., Hallmans G., Rinaldi S., et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer, a prospective study in northern Sweden. Gut 50 (2002) 642-646
24. Kirman I., Poltoratskaia N., Sylla P., and Whelan R.L. Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. Surgery 136 (2004) 205-209
25. Brodt P. Characterization of two highly metastatic variants of Lewis lung carcinoma with different organ specificities. Cancer Res. 46 (1986) 2442-2448
26. Jerome L., Alami N., Belanger S., et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 66 (2006) 7245-7252
27. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships, the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
28. Jenkins P.J., Khalaf S., Ogunkolade W., et al. Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis. Endocrinol. Relat. Cancer 12 (2005) 891-901
29. Lee H.Y., Moon H., Chun K.H., et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J. Natl. Cancer Inst. 96 (2004) 1536-1548
30. Samani A.A., Yakar S., Leroith D., and Brodt P. The role of the IGF system in cancer growth and metastasis, overview and recent insights. Endocrinol. Rev. (2006)
31. Sachdev D., and Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 6 (2007) 1-12
32. Modric T., Silha J.V., Shi Z., et al. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology 142 (2001) 1958-1967
33. Liu B., Lee K.W., Anzo M., et al. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene (2006)
34. Liu B., Lee K.W., Li H., et al. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin. Cancer Res. 11 (2005) 4851-4856
35. Kim H.S., Ingermann A.R., Tsubaki J., et al. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. 64 (2004) 2229-2237
36. Kelly R.G., Nally K., Shanahan F., and O'Connell J. Type I insulin-like growth factor receptor expression on colorectal adenocarcinoma cell lines is decreased in response to the chemopreventive agent N-acetyl-l-cysteine. Ann. NY Acad. Sci. 973 (2002) 555-558
37. Fuertes M.A., Alonso C., and Perez J.M. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 103 (2003) 645-662
38. Akagi Y., Liu W., Xie K., et al. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta. Br. J. Cancer 80 (1999) 1506-1511